Sign up to save your podcasts
Or
Share New insights on PU.1-mutated agammaglobulinemia; venetoclax-based induction therapy in younger AML patients; the link between ABO Blood groups and risk of future VTE
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
New insights on PU.1-mutated agammaglobulinemia; venetoclax-based induction therapy in younger AML patients; the link between ABO Blood groups and risk of future VTE
In this week's episode, we'll hear about new insights into PU.1-mutated agammaglobulinemia. Researchers show that haploinsufficiency of the master transcriptional regulator PU.1 causes agammaglobulinemia and dendritic cell deficiencies. These patients experience an array of infectious and non-infectious complications, but not leukemia. After that: venetoclax-based induction therapy in younger patients with AML. Venetoclax plus decitabine was associated with superior safety and non-inferior response rates compared to intensive chemotherapy. Is it time to consider lower-intensity therapy beyond older and unfit patients? Finally, a focus on venous thromboembolism. Researchers link BGAT, an enzyme pivotal to determining blood type, to risk of future VTE. They say high plasma levels of BGAT contribute to risk above and beyond what can be explained by von Willebrand factor and Factor VIII.
Featured Articles:
- One hundred thirty-four germ line PU.1 variants and the agammaglobulinemic patients carrying them
- Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML
- Histo–blood group ABO system transferase plasma levels and risk of future venous thromboembolism: the HUNT study
View all episodes
By American Society of Hematology
4.1
4848 ratings
In this week's episode, we'll hear about new insights into PU.1-mutated agammaglobulinemia. Researchers show that haploinsufficiency of the master transcriptional regulator PU.1 causes agammaglobulinemia and dendritic cell deficiencies. These patients experience an array of infectious and non-infectious complications, but not leukemia. After that: venetoclax-based induction therapy in younger patients with AML. Venetoclax plus decitabine was associated with superior safety and non-inferior response rates compared to intensive chemotherapy. Is it time to consider lower-intensity therapy beyond older and unfit patients? Finally, a focus on venous thromboembolism. Researchers link BGAT, an enzyme pivotal to determining blood type, to risk of future VTE. They say high plasma levels of BGAT contribute to risk above and beyond what can be explained by von Willebrand factor and Factor VIII.
Featured Articles:
- One hundred thirty-four germ line PU.1 variants and the agammaglobulinemic patients carrying them
- Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML
- Histo–blood group ABO system transferase plasma levels and risk of future venous thromboembolism: the HUNT study
More shows like Blood Podcast
View all
JAMA Editors' Summary
129 Listeners
Hematologic Oncology Update
72 Listeners
NEJM This Week
318 Listeners
The Hematologist
26 Listeners
JAMA Clinical Reviews
487 Listeners
Mayo Clinic Talks
270 Listeners
VJHemOnc Podcast
2 Listeners
Annals On Call Podcast
184 Listeners
The Curious Clinicians
362 Listeners
The BSH Guidelines Official Podcast
3 Listeners
EHA Unplugged
2 Listeners
WolverHeme Happy Hour
29 Listeners
Two Onc Docs
166 Listeners
Blood Cancer Talks
48 Listeners
HemeTalks: Conversations in Hematology Education
1 Listeners